search
Back to results

Cytidine and Omega-3 Fatty Acids in Bipolar Disorder

Primary Purpose

Bipolar Disorder

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
cytidine
omega-3 fatty acids
placebo
Sponsored by
Mclean Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Bipolar Disorder focused on measuring bipolar disorder, bipolar depression, bipolar mania, manic depression, depression, mania, hypomania

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • bipolar disorder
  • mood episode within past year
  • stable medication regimen

Exclusion Criteria:

  • primary psychiatric disorder other than bipolar disorder
  • significant suicide or homicide risk
  • unstable medical conditions
  • current or planned pregnancy
  • lactose intolerance
  • medications affecting lipid absorption or metabolism
  • clozapine treatment

Sites / Locations

  • McLean Hospital
  • Jersey Shore University Medical Center

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Placebo Comparator

Arm Label

1

2

placebo

Arm Description

Omega-3 fatty acid and cytidine supplementation

omega-3 fatty acid supplementation

placeno or sugar pill

Outcomes

Primary Outcome Measures

Mood Rating Scale Scores

Secondary Outcome Measures

Study Retention Time
functional recovery

Full Information

First Posted
February 27, 2009
Last Updated
April 19, 2012
Sponsor
Mclean Hospital
Collaborators
Stanley Medical Research Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT00854737
Brief Title
Cytidine and Omega-3 Fatty Acids in Bipolar Disorder
Official Title
A Combination of Cytidine and Omega-3 Fatty Acids in Bipolar Disorder: Are There Additive or Synergistic Mood Stabilizing Effects?
Study Type
Interventional

2. Study Status

Record Verification Date
April 2012
Overall Recruitment Status
Completed
Study Start Date
July 2004 (undefined)
Primary Completion Date
August 2007 (Actual)
Study Completion Date
July 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mclean Hospital
Collaborators
Stanley Medical Research Institute

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The goal of the proposed clinical trial is to assess the effect of oral cytidine and omega-3 fatty acids (O3FA) on bipolar disorder symptoms. This study is a 4-month, randomized, parallel-group, double-blind, placebo-controlled pilot study of a combination of cytidine and omega-3 fatty acids in 90 recently ill subjects with bipolar disorder. During the 16 week period of the study, subjects are assigned to one of three groups: 1) omega-3 fatty acids + cytidine supplementation, 2) omega-3 fatty acids supplementation alone, and 3) placebo supplementation.
Detailed Description
Previous studies examining the effect of omega-3 fatty acids on bipolar depression have had mixed results. Some studies have found that omega-3 fatty acids have a positive effect on bipolar depression symptoms, while other studies have found no difference between placebo and omega-3 fatty acid treatment. The variable effects noted with omega-3 fatty acids may be due in part to a real effect with limited potency. Larger effects might be achieved by combining agents with synergistic effects. Cytidine is necessary to form key intermediates in the biosynthesis of the phospholipids phosphatidylcholine and phosphatidylethanolamine, which are major components of eukaryotic cell membranes. Recent human studies by our group have shown that CDP-choline (a compound composed of cytidine and choline) can modify brain phospholipid synthesis in healthy adults and may have antidepressant effects (Babb et al., 1996; Babb et al., 2002; Carlezon et al., 2002; Renshaw et al., 1999). The combination of omega-fatty acids and the related pyrimidine, uridine, was associated with enhanced antidepressant-like activity in rats (Carlezon et al., 2005). Thus, the combination of omega-3 fatty acid and cytidine, which is interconverted with uridine in the body, may provide a safe and powerful way to treat bipolar disorder, especially bipolar depression. This study is a 4-month, randomized, parallel-group, double-blind, placebo-controlled pilot study of a combination of cytidine and omega-3 fatty acids in 90 recently ill subjects with bipolar disorder. During the 16 week period of the study, subjects are assigned to one of three groups: 1) omega-3 fatty acids + cytidine supplementation, 2) omega-3 fatty acids supplementation alone, and 3) placebo supplementation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bipolar Disorder
Keywords
bipolar disorder, bipolar depression, bipolar mania, manic depression, depression, mania, hypomania

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
90 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Active Comparator
Arm Description
Omega-3 fatty acid and cytidine supplementation
Arm Title
2
Arm Type
Active Comparator
Arm Description
omega-3 fatty acid supplementation
Arm Title
placebo
Arm Type
Placebo Comparator
Arm Description
placeno or sugar pill
Intervention Type
Dietary Supplement
Intervention Name(s)
cytidine
Intervention Description
cytidine (2g po daily for 4 months)
Intervention Type
Dietary Supplement
Intervention Name(s)
omega-3 fatty acids
Intervention Description
omega-3 fatty acids (4g po daily for 4 months)
Intervention Type
Drug
Intervention Name(s)
placebo
Other Intervention Name(s)
arm 2 and 3
Intervention Description
sugar pill
Primary Outcome Measure Information:
Title
Mood Rating Scale Scores
Time Frame
weekly-biweekly
Secondary Outcome Measure Information:
Title
Study Retention Time
Time Frame
4 months
Title
functional recovery
Time Frame
weekly-biweekly

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: bipolar disorder mood episode within past year stable medication regimen Exclusion Criteria: primary psychiatric disorder other than bipolar disorder significant suicide or homicide risk unstable medical conditions current or planned pregnancy lactose intolerance medications affecting lipid absorption or metabolism clozapine treatment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Beth L Murphy, MD, PhD
Organizational Affiliation
Mclean Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
McLean Hospital
City
Belmont
State/Province
Massachusetts
ZIP/Postal Code
02478
Country
United States
Facility Name
Jersey Shore University Medical Center
City
Neptune
State/Province
New Jersey
ZIP/Postal Code
07753
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
8888372
Citation
Babb SM, Appelmans KE, Renshaw PF, Wurtman RJ, Cohen BM. Differential effect of CDP-choline on brain cytosolic choline levels in younger and older subjects as measured by proton magnetic resonance spectroscopy. Psychopharmacology (Berl). 1996 Sep;127(2):88-94. doi: 10.1007/BF02805979.
Results Reference
background
PubMed Identifier
12021827
Citation
Babb SM, Wald LL, Cohen BM, Villafuerte RA, Gruber SA, Yurgelun-Todd DA, Renshaw PF. Chronic citicoline increases phosphodiesters in the brains of healthy older subjects: an in vivo phosphorus magnetic resonance spectroscopy study. Psychopharmacology (Berl). 2002 May;161(3):248-54. doi: 10.1007/s00213-002-1045-y. Epub 2002 Mar 22.
Results Reference
background
PubMed Identifier
15705349
Citation
Carlezon WA Jr, Mague SD, Parow AM, Stoll AL, Cohen BM, Renshaw PF. Antidepressant-like effects of uridine and omega-3 fatty acids are potentiated by combined treatment in rats. Biol Psychiatry. 2005 Feb 15;57(4):343-50. doi: 10.1016/j.biopsych.2004.11.038.
Results Reference
background
PubMed Identifier
10232294
Citation
Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, Cress KK, Marangell LB. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1999 May;56(5):407-12. doi: 10.1001/archpsyc.56.5.407.
Results Reference
background
PubMed Identifier
12022961
Citation
Carlezon WA, Pliakas AM, Parow AM, Detke MJ, Cohen BM, Renshaw PF. Antidepressant-like effects of cytidine in the forced swim test in rats. Biol Psychiatry. 2002 Jun 1;51(11):882-9. doi: 10.1016/s0006-3223(01)01344-0.
Results Reference
background
PubMed Identifier
22926607
Citation
Murphy BL, Stoll AL, Harris PQ, Ravichandran C, Babb SM, Carlezon WA Jr, Cohen BM. Omega-3 fatty acid treatment, with or without cytidine, fails to show therapeutic properties in bipolar disorder: a double-blind, randomized add-on clinical trial. J Clin Psychopharmacol. 2012 Oct;32(5):699-703. doi: 10.1097/JCP.0b013e318266854c.
Results Reference
derived
Links:
URL
http://www.mclean.harvard.edu
Description
hospital website with links to research group and studies

Learn more about this trial

Cytidine and Omega-3 Fatty Acids in Bipolar Disorder

We'll reach out to this number within 24 hrs